• 2023.0306

    The Development of Reporting Guideline of clinical Practice Guidelines in General Practice provides detailed guidance for the makers and writers of the general practice guidelines, which will further improve the reporting quality of the general practice guidelines, especially the Chinese general practice guidelines, and promote the application in general medical practice, thus finally improving the quality of primary medical care.

  • 2023.0220

    Professor Gordon Guyatt of McMaster University and Professor Victor Montori of the Mayo Clinic jointly published a paper in the British Medical Journal (BMJ) entitled: Guidelines should consider clinicians' time needed to treat on January 3, 2023.

  • 2022.1126

    IGEST is a generic tool for screening guidelines for any specialty, target population, and healthcare organization, but it is intended only as a screening tool, primarily for quickly assessing guideline quality and determining whether they can be adopted or adapted in other settings, and is not a substitute for some of the more complex guideline quality evaluation tools.

  • 2022.1031

    In July 2022, Jose F. Meneses-Echavez et al. from the Norwegian Institute of Public Health published an article in the Journal of Clinical Epidemiology entitled "Evidence to decision frameworks enabled structured and explicit development of healthcare recommendations". The aim of this study was to identify and describe the processes suggested for the formulation of healthcare recommendations in healthcare guidelines available in guidance documents.

Register MORE
  • 2023.0607
  • 2023.0607
    The consensus mainly focuses on pharmaceutical management of immunosuppressive application after organ transplantation, drug management of infection prevention and treatment, metabolic disease complications, tumor, and comprehensive management of quality of life. The aim of the consensus is to improve long-term follow-up and management level after transplantation, promote standardization and homogenization of pharmaceutical care and practice after transplantation, and improve the quality of life and long-term survival of transplant recipients.
  • 2023.0607
    Biliary atresia (BA) progresses rapidly and early diagnosis is very important. If not treated in time, biliary cirrhosis, portal hypertension, and even liver failure may occur. Kasai portoenterostomy (KPE) is the first choice of treatment, the 5-year survival rate of autologous liver after the operation is about 80%. Around 75% of patients need to perform liver transplants finally, the 10-year survival rate is about 60%. Accordingly, the treatment of BA is necessary while the treatment efficacy is still unsatisfactory in some patients. Although KPE has been performed widely, the post-operative regulation strategy is still not unified, and some patients have liver transplants very early after KPE. In summary, the diagnosing and treatment strategy is not standardized and unified. BA has imposed a huge economic and medical resources burden on families and societies, and some families of patients chose to give up treatment. Therefore, it is necessary and of great significance to draw up an international guideline for diagnosing & treating BA. This guideline aims to help doctors diagnose and treat the disease, provide the latest insight for pediatric surgeons who are appropriate to perform KPE, prompt pediatric liver transplant surgeons what are appropriate surgical indications for liver transplantation in necessary situations, and guide how to manage after the operation.
Registration process and operational mode of a CPG registry